Increases Full Year 2021 Earnings Guidance
|
Quarter ended |
|
Six months ended |
|||||
|
|
|
|
|||||
|
2021 |
|
2020 |
|
2021 |
|
2020 |
|
|
|
|
|
|
|
|
|
|
|
(In millions, except per-share results) |
|||||||
Premium Revenue |
|
|
|
|
|
|
|
|
Total Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP: |
|
|
|
|
|
|
|
|
Net Income |
|
|
|
|
|
|
|
|
EPS – Diluted |
|
|
|
|
|
|
|
|
Medical Care Ratio (MCR) |
88.4% |
|
82.3% |
|
87.6% |
|
84.3% |
|
G&A Ratio |
7.1% |
|
7.5% |
|
7.2% |
|
7.2% |
|
After-tax Margin |
2.7% |
|
6.0% |
|
3.1% |
|
5.0% |
|
|
|
|
|
|
|
|
|
|
Adjusted: |
|
|
|
|
|
|
|
|
Net Income |
|
|
|
|
|
|
|
|
EPS – Diluted |
|
|
|
|
|
|
|
|
G&A Ratio |
6.9% |
|
7.5% |
|
7.0% |
|
7.2% |
|
After-tax Margin |
2.9% |
|
6.2% |
|
3.4% |
|
5.1% |
|
See the Reconciliation of Unaudited Non-GAAP Financial Measures at the end of this release. |
Quarter Highlights
-
GAAP net income for the second quarter of 2021 was
$185 million , or$3.16 per diluted share. -
Adjusted net income for the second quarter of 2021 was
$199 million , or$3.40 per diluted share. -
As of
June 30, 2021 , the Company served approximately 4.7 million members, an increase of 1.1 million members, or 32%, compared toJune 30, 2020 . -
Premium revenue was approximately
$6.6 billion for the second quarter of 2021, an increase of 51% compared to the second quarter of 2020. -
The net effect of COVID decreased net income by approximately
$1.00 per diluted share in the second quarter of 2021. -
The Company increased its full year 2021 premium revenue guidance to more than
$25.0 billion , from its previous guidance of more than$24.0 billion . -
The Company increased its full year 2021 adjusted earnings guidance to no less than
$13.25 per diluted share, from its previous guidance of no less than$13.00 per diluted share.
“We are pleased with our second quarter and year to date results as we continue to produce solid margin performance despite the challenges created by the pandemic,” said
Premium Revenue
Premium revenue was approximately
Net Income
Net income for the second quarter was
The year over year comparison reflects the negative impact from the net effect of COVID in the second quarter of 2021 while, in contrast, the prior year quarter was positively impacted by the net effect of COVID.
Net income for the six months ended
Medical Care Ratio
The consolidated MCR for the second quarter was 88.4%, compared to 82.3% in the second quarter of 2020. The net effect of COVID increased the consolidated MCR by 110 basis points and impacted all three lines of business. In the prior year, the net effect of COVID decreased the consolidated MCR by approximately 350 basis points.
A year-over-year comparison is less meaningful than it would be in a typical year. The second quarter of 2020 was the first full quarter of the COVID pandemic, and was distorted by the significant positive net effect of COVID that characterized that early phase of the crisis. In contrast, the current quarter was negatively impacted by the net effect of COVID. Therefore, a sequential MCR comparison is more relevant.
On a sequential basis, the consolidated MCR for the second quarter was 88.4%, compared to 86.8% in the first quarter of 2021. The net effect of COVID increased the consolidated MCR by 110 basis points in the second quarter of 2021 and was negligible the first quarter.
- Medicaid MCR: Increased to 89.0% compared to 87.5% for the first quarter of 2021. The increase in the MCR was primarily due to the net effect of COVID.
- Medicare MCR: Decreased to 87.6% compared to 90.3% in the first quarter of 2021. The decrease in the MCR was primarily due to the lower negative net effect of COVID and improved underlying performance compared to the first quarter.
- Marketplace MCR: Increased to 84.8% compared to 77.3% for the first quarter of 2021. The impact from the net effect of COVID in the second quarter was approximately 500 basis points, consistent with the first quarter, due to continued COVID utilization pressure in many geographies. The sequential increase in the MCR primarily reflects normal seasonality.
General and Administrative Expense Ratio
The G&A ratio for the second quarter was 7.1%, compared to 7.5% for the second quarter of 2020. The adjusted G&A ratio for the second quarter was 6.9%, compared to 7.5% for the second quarter of 2020 reflecting disciplined cost management and the benefits of fixed cost leverage produced by substantial revenue growth.
Balance Sheet
Cash and investments at the parent company amounted to
Cash Flow
Operating cash flow for the six months ended
2021 Guidance
The Company now expects its full year 2021 total revenue to be more than
Premium revenue guidance is now expected to be more than
The Company increased its full year 2021 adjusted earnings per share guidance to be no less than
Revised guidance reflects:
- Updated assumptions for the Public Health Emergency period, and the associated pause on Medicaid membership redeterminations, which is now expected to continue through the fourth quarter of 2021;
-
Retention of pharmacy related premium in
California ,New York , andKentucky ; - Underlying outperformance;
-
Offset by an increase in the estimated net effect of COVID by
$1.00 per share which is now expected to be approximately$2.50 per share for the full year; and - Continued caution in forecasting utilization trends in the remaining six months of the year due to the COVID pandemic.
The impact of the Affinity and the Cigna Texas membership acquisitions are not included.
See the Reconciliation of Unaudited Non-GAAP Financial Measures at the end of this release.
Conference Call
Management will host a conference call and webcast to discuss Molina Healthcare’s second quarter 2021 results at
About
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This earnings release and the Company’s accompanying oral remarks contain forward-looking statements regarding its 2021 guidance, as well as its plans, expectations, and the Company’s expectations regarding future developments. Actual results could differ materially due to numerous known and unknown risks and uncertainties. These risks and uncertainties are discussed under the headings “Forward-Looking Statements,” and “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended
These reports can be accessed under the investor relations tab of the Company’s website or on the SEC’s website at sec.gov. Given these risks and uncertainties, the Company can give no assurances that its forward-looking statements will prove to be accurate, or that any other results or developments projected or contemplated by its forward-looking statements will in fact occur, and the Company cautions investors not to place undue reliance on these statements. All forward-looking statements in this release represent the Company’s judgment as of
|
||||||||||||||||
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME |
||||||||||||||||
|
Three Months Ended |
|
Six Months Ended |
|||||||||||||
|
|
|
|
|||||||||||||
|
2021 |
|
2020 |
|
2021 |
|
2020 |
|||||||||
|
|
|
|
|
|
|
|
|||||||||
|
(In millions, except per-share amounts) |
|||||||||||||||
Revenue: |
|
|
|
|
|
|
|
|||||||||
Premium revenue |
$ |
6,583 |
|
|
$ |
4,372 |
|
|
$ |
12,889 |
|
|
$ |
8,676 |
|
|
Premium tax revenue |
185 |
|
|
157 |
|
|
372 |
|
|
307 |
|
|||||
Health insurer fees reimbursed |
— |
|
|
71 |
|
|
— |
|
|
137 |
|
|||||
Investment income |
10 |
|
|
13 |
|
|
19 |
|
|
38 |
|
|||||
Other revenue |
22 |
|
|
5 |
|
|
42 |
|
|
9 |
|
|||||
Total revenue |
6,800 |
|
|
4,618 |
|
|
13,322 |
|
|
9,167 |
|
|||||
Operating expenses: |
|
|
|
|
|
|
|
|||||||||
Medical care costs |
5,819 |
|
|
3,598 |
|
|
11,293 |
|
|
7,314 |
|
|||||
General and administrative expenses |
484 |
|
|
345 |
|
|
957 |
|
|
662 |
|
|||||
Premium tax expenses |
185 |
|
|
157 |
|
|
372 |
|
|
307 |
|
|||||
Health insurer fees |
— |
|
|
71 |
|
|
— |
|
|
139 |
|
|||||
Depreciation and amortization |
31 |
|
|
21 |
|
|
64 |
|
|
41 |
|
|||||
Other |
8 |
|
|
2 |
|
|
28 |
|
|
6 |
|
|||||
Total operating expenses |
6,527 |
|
|
4,194 |
|
|
12,714 |
|
|
8,469 |
|
|||||
Operating income |
273 |
|
|
424 |
|
|
608 |
|
|
698 |
|
|||||
Other expenses, net: |
|
|
|
|
|
|
|
|||||||||
Interest expense |
30 |
|
|
24 |
|
|
60 |
|
|
45 |
|
|||||
Other expense, net |
— |
|
|
5 |
|
|
— |
|
|
5 |
|
|||||
Total other expenses, net |
30 |
|
|
29 |
|
|
60 |
|
|
50 |
|
|||||
Income before income tax expense |
243 |
|
|
395 |
|
|
548 |
|
|
648 |
|
|||||
Income tax expense |
58 |
|
|
119 |
|
|
135 |
|
|
194 |
|
|||||
Net income |
$ |
185 |
|
|
$ |
276 |
|
|
$ |
413 |
|
|
$ |
454 |
|
|
|
|
|
|
|
|
|
|
|||||||||
Net income per share – Diluted |
$ |
3.16 |
|
|
$ |
4.65 |
|
|
$ |
7.05 |
|
|
$ |
7.54 |
|
|
|
|
|
|
|
|
|
|
|||||||||
Diluted weighted average shares outstanding |
58.4 |
|
|
59.4 |
|
|
58.5 |
|
|
60.2 |
|
|||||
|
|
|
|
|
|
|
|
|||||||||
Operating Statistics: |
|
|
|
|
|
|
|
|||||||||
Medical care ratio |
88.4 |
% |
|
82.3 |
% |
|
87.6 |
% |
|
84.3 |
% |
|||||
G&A ratio |
7.1 |
% |
|
7.5 |
% |
|
7.2 |
% |
|
7.2 |
% |
|||||
Premium tax ratio |
2.7 |
% |
|
3.5 |
% |
|
2.8 |
% |
|
3.4 |
% |
|||||
Effective income tax rate |
24.2 |
% |
|
30.0 |
% |
|
24.7 |
% |
|
29.9 |
% |
|||||
After-tax margin |
2.7 |
% |
|
6.0 |
% |
|
3.1 |
% |
|
5.0 |
% |
|||||
|
|
|
|
|
|
|
|
|
||||||||
CONSOLIDATED BALANCE SHEETS |
||||||||
|
|
|
|
|||||
|
2021 |
|
2020 |
|||||
|
Unaudited |
|
|
|||||
|
(Dollars in millions, except per-share amounts) |
|||||||
ASSETS |
||||||||
Current assets: |
|
|
|
|||||
Cash and cash equivalents |
$ |
4,608 |
|
|
$ |
4,154 |
|
|
Investments |
2,241 |
|
|
1,875 |
|
|||
Receivables |
1,857 |
|
|
1,672 |
|
|||
Prepaid expenses and other current assets |
168 |
|
|
175 |
|
|||
Total current assets |
8,874 |
|
|
7,876 |
|
|||
Property, equipment, and capitalized software, net |
383 |
|
|
391 |
|
|||
|
929 |
|
|
941 |
|
|||
Restricted investments |
145 |
|
|
136 |
|
|||
Deferred income taxes |
65 |
|
|
69 |
|
|||
Other assets |
134 |
|
|
119 |
|
|||
Total assets |
$ |
10,530 |
|
|
$ |
9,532 |
|
|
|
|
|
|
|||||
LIABILITIES AND STOCKHOLDERS’ EQUITY |
||||||||
Current liabilities: |
|
|
|
|||||
Medical claims and benefits payable |
$ |
2,942 |
|
|
$ |
2,696 |
|
|
Amounts due government agencies |
2,072 |
|
|
1,253 |
|
|||
Accounts payable, accrued liabilities and other |
651 |
|
|
641 |
|
|||
Deferred revenue |
42 |
|
|
375 |
|
|||
Total current liabilities |
5,707 |
|
|
4,965 |
|
|||
Long-term debt |
2,129 |
|
|
2,127 |
|
|||
Finance lease liabilities |
223 |
|
|
225 |
|
|||
Other long-term liabilities |
101 |
|
|
119 |
|
|||
Total liabilities |
8,160 |
|
|
7,436 |
|
|||
Stockholders’ equity: |
|
|
|
|||||
Common stock, |
— |
|
|
— |
|
|||
Preferred stock, |
— |
|
|
— |
|
|||
Additional paid-in capital |
191 |
|
|
199 |
|
|||
Accumulated other comprehensive income |
26 |
|
|
37 |
|
|||
Retained earnings |
2,153 |
|
|
1,860 |
|
|||
Total stockholders’ equity |
2,370 |
|
|
2,096 |
|
|||
Total liabilities and stockholders’ equity |
$ |
10,530 |
|
|
$ |
9,532 |
|
|
|
|
|
|
|
||||||||
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||||||
|
Six Months Ended |
|||||||
|
|
|||||||
|
2021 |
|
2020 |
|||||
|
|
|
|
|||||
|
(in millions) |
|||||||
Operating activities: |
|
|
|
|||||
Net income |
$ |
413 |
|
|
$ |
454 |
|
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|||||
Depreciation and amortization |
64 |
|
|
41 |
|
|||
Deferred income taxes |
7 |
|
|
6 |
|
|||
Share-based compensation |
35 |
|
|
28 |
|
|||
Loss on debt repayment |
— |
|
|
5 |
|
|||
Other, net |
10 |
|
|
(1) |
|
|||
Changes in operating assets and liabilities: |
|
|
|
|||||
Receivables |
(192) |
|
|
(174) |
|
|||
Prepaid expenses and other current assets |
(6) |
|
|
(157) |
|
|||
Medical claims and benefits payable |
272 |
|
|
106 |
|
|||
Amounts due government agencies |
792 |
|
|
201 |
|
|||
Accounts payable, accrued liabilities and other |
(15) |
|
|
259 |
|
|||
Deferred revenue |
(333) |
|
|
(195) |
|
|||
Income taxes |
14 |
|
|
184 |
|
|||
Net cash provided by operating activities |
1,061 |
|
|
757 |
|
|||
Investing activities: |
|
|
|
|||||
Purchases of investments |
(1,006) |
|
|
(670) |
|
|||
Proceeds from sales and maturities of investments |
622 |
|
|
750 |
|
|||
Purchases of property, equipment, and capitalized software |
(29) |
|
|
(45) |
|
|||
Other, net |
5 |
|
|
3 |
|
|||
Net cash (used in) provided by investing activities |
(408) |
|
|
38 |
|
|||
Financing activities: |
|
|
|
|||||
Common stock purchases |
(128) |
|
|
(453) |
|
|||
Common stock withheld to settle employee tax obligations |
(52) |
|
|
(8) |
|
|||
Contingent consideration liabilities settled |
(20) |
|
|
— |
|
|||
Proceeds from senior notes offering, net of issuance costs |
— |
|
|
789 |
|
|||
Repayment of term loan facility |
— |
|
|
(600) |
|
|||
Proceeds from borrowings under term loan facility |
— |
|
|
380 |
|
|||
Other, net |
— |
|
|
(45) |
|
|||
Net cash (used in) provided by financing activities |
(200) |
|
|
63 |
|
|||
Net increase in cash, cash equivalents, and restricted cash and cash equivalents |
453 |
|
|
858 |
|
|||
Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period |
4,223 |
|
|
2,508 |
|
|||
Cash, cash equivalents, and restricted cash and cash equivalents at end of period |
$ |
4,676 |
|
|
$ |
3,366 |
|
|
|
|
|
|
|
||||||||||
UNAUDITED SEGMENT DATA |
||||||||||
(Dollars in millions) |
||||||||||
|
|
|
|
|
|
|
||||
|
|
2021 (1) |
|
2020 |
|
2020 |
||||
Ending Membership by Segment: |
|
|
|
|
|
|||||
Medicaid |
3,928,000 |
|
|
3,599,000 |
|
|
3,122,000 |
|
||
Medicare |
130,000 |
|
|
115,000 |
|
|
108,000 |
|
||
Marketplace |
638,000 |
|
|
318,000 |
|
|
325,000 |
|
||
Total |
4,696,000 |
|
|
4,032,000 |
|
|
3,555,000 |
|
||
|
|
|
|
|
|
|
||||
(1) Approximately 200,000 members, from the Magellan Complete Care acquisition that closed on |
|
Three Months Ended |
|||||||||||||||||||||
|
2021 |
|
2020 |
|||||||||||||||||||
|
Premium
|
|
Medical Margin |
|
MCR (1) |
|
Premium
|
|
Medical Margin |
|
MCR (1) |
|||||||||||
|
|
|
|
|
|
|||||||||||||||||
Medicaid |
$ |
4,840 |
|
|
$ |
604 |
|
|
87.5 |
% |
|
$ |
3,286 |
|
|
$ |
365 |
|
|
88.9 |
% |
|
Medicare |
799 |
|
|
77 |
|
|
90.3 |
|
|
634 |
|
|
117 |
|
|
81.7 |
|
|||||
Marketplace |
667 |
|
|
151 |
|
|
77.3 |
|
|
384 |
|
|
106 |
|
|
72.3 |
|
|||||
Consolidated |
$ |
6,306 |
|
|
$ |
832 |
|
|
86.8 |
% |
|
$ |
4,304 |
|
|
$ |
588 |
|
|
86.3 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Three Months Ended |
|||||||||||||||||||||
|
2021 |
|
2020 |
|||||||||||||||||||
|
Premium
|
|
Medical Margin |
|
MCR (1) |
|
Premium
|
|
Medical Margin |
|
MCR (1) |
|||||||||||
|
|
|
|
|
|
|||||||||||||||||
Medicaid |
$ |
5,034 |
|
|
$ |
551 |
|
|
89.0 |
% |
|
$ |
3,375 |
|
|
$ |
553 |
|
|
83.6 |
% |
|
Medicare |
814 |
|
|
101 |
|
|
87.6 |
|
|
630 |
|
|
125 |
|
|
80.0 |
|
|||||
Marketplace |
735 |
|
|
112 |
|
|
84.8 |
|
|
367 |
|
|
96 |
|
|
74.0 |
|
|||||
Consolidated |
$ |
6,583 |
|
|
$ |
764 |
|
|
88.4 |
% |
|
$ |
4,372 |
|
|
$ |
774 |
|
|
82.3 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Six Months Ended |
|||||||||||||||||||||
|
2021 |
|
2020 |
|||||||||||||||||||
|
Premium
|
|
Medical Margin |
|
MCR (1) |
|
Premium
|
|
Medical Margin |
|
MCR (1) |
|||||||||||
|
|
|
|
|
|
|||||||||||||||||
Medicaid |
$ |
9,874 |
|
|
$ |
1,155 |
|
|
88.3 |
% |
|
$ |
6,661 |
|
|
$ |
918 |
|
|
86.2 |
% |
|
Medicare |
1,613 |
|
|
178 |
|
|
89.0 |
|
|
1,264 |
|
|
242 |
|
|
80.8 |
|
|||||
Marketplace |
1,402 |
|
|
263 |
|
|
81.2 |
|
|
751 |
|
|
202 |
|
|
73.1 |
|
|||||
Consolidated |
$ |
12,889 |
|
|
$ |
1,596 |
|
|
87.6 |
% |
|
$ |
8,676 |
|
|
$ |
1,362 |
|
|
84.3 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
(1) The MCR represents medical costs as a percentage of premium revenue. |
CHANGE IN MEDICAL CLAIMS AND BENEFITS PAYABLE
(Dollars in millions)
The Company’s claims liabilities include additional reserves to account for moderately adverse conditions based on historical experience and other factors including, but not limited to, variations in claims payment patterns, changes in utilization and cost trends, known outbreaks of disease, and large claims. The Company’s reserving methodology is consistently applied across all periods presented. The amounts displayed for “Components of medical care costs related to: Prior year” represent the amounts by which the original estimates of claims and benefits payable at the beginning of the year were more than the actual liabilities based on information (principally the payment of claims) developed since those liabilities were first reported. The following table presents the components of the change in medical claims and benefits payable for the periods indicated:
|
Six Months Ended |
|||||||
|
|
|||||||
|
2021 |
|
2020 |
|||||
|
|
|
|
|||||
|
Unaudited |
|||||||
Medical claims and benefits payable, beginning balance |
$ |
2,696 |
|
|
$ |
1,854 |
|
|
Components of medical care costs related to: |
|
|
|
|||||
Current year |
11,486 |
|
|
7,372 |
|
|||
Prior year |
(193) |
|
|
(58) |
|
|||
Total medical care costs |
11,293 |
|
|
7,314 |
|
|||
Payments for medical care costs related to: |
|
|
|
|||||
Current year |
9,023 |
|
|
5,688 |
|
|||
Prior year |
1,949 |
|
|
1,486 |
|
|||
Total paid |
10,972 |
|
|
7,174 |
|
|||
Change in acquired balances |
(26) |
|
|
— |
|
|||
Change in non-risk and other provider payables |
(49) |
|
|
(34) |
|
|||
Medical claims and benefits payable, ending balance |
$ |
2,942 |
|
|
$ |
1,960 |
|
|
|
|
|
|
|||||
Days in claims payable, fee for service (1) |
48 |
|
|
52 |
|
|||
__________________ |
|
|
|
|||||
(1) Claims payable includes primarily claims incurred but not paid, or IBNP. It also includes certain fee-for-service payables reported in medical claims and benefits payable amounting to |
RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES
(In millions, except per diluted share amounts)
The Company believes that certain non-GAAP (generally accepted accounting principles) financial measures are useful supplemental measures to investors in comparing the Company’s performance to the performance of other public companies in the health care industry. The non-GAAP financial measures are also used internally to enable management to assess the Company’s performance consistently over time. These non-GAAP financial measures, presented below, should be considered as supplements to, and not as substitutes for or superior to, GAAP measures.
Adjustments represent additions and deductions to GAAP net income as indicated in the table below, which include the non-cash impact of amortization of acquired intangible assets, acquisition-related expenses, and the impact of certain expenses and other items that management believes are not indicative of longer-term business trends and operations.
Adjusted G&A Ratio represents the GAAP G&A ratio, recognizing adjustments.
Adjusted net income represents GAAP net income recognizing the adjustments, net of tax. The Company believes that adjusted net income is helpful to investors in assessing the Company’s financial performance.
Adjusted net income per diluted share represents adjusted net income divided by weighted average common shares outstanding on a fully diluted basis.
Adjusted after-tax margin represents adjusted net income, divided by total revenue.
|
Three Months Ended |
|
Six Months Ended |
|||||||||||||||||||||||||||||
2021 |
|
2020 |
|
2021 |
|
2020 |
||||||||||||||||||||||||||
|
Amount |
|
Per
|
|
Amount |
|
Per
|
|
Amount |
|
Per
|
|
Amount |
|
Per
|
|||||||||||||||||
Net income |
$ |
185 |
|
|
$ |
3.16 |
|
|
$ |
276 |
|
|
$ |
4.65 |
|
|
$ |
413 |
|
|
$ |
7.05 |
|
|
$ |
454 |
|
|
$ |
7.54 |
|
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Acquisition-related expenses (1) |
6 |
|
|
0.11 |
|
|
— |
|
|
— |
|
|
27 |
|
|
0.46 |
|
|
— |
|
|
— |
|
|||||||||
Amortization of intangible assets |
12 |
|
|
0.20 |
|
|
4 |
|
|
0.06 |
|
|
24 |
|
|
0.40 |
|
|
8 |
|
|
0.13 |
|
|||||||||
Loss on debt repayment |
— |
|
|
— |
|
|
5 |
|
|
0.08 |
|
|
— |
|
|
— |
|
|
5 |
|
|
0.08 |
|
|||||||||
Other (2) |
— |
|
|
— |
|
|
2 |
|
|
0.04 |
|
|
9 |
|
|
0.16 |
|
|
6 |
|
|
0.11 |
|
|||||||||
Subtotal, adjustments |
18 |
|
|
0.31 |
|
|
11 |
|
|
0.18 |
|
|
60 |
|
|
1.02 |
|
|
19 |
|
|
0.32 |
|
|||||||||
Income tax effect |
(4) |
|
|
(0.07) |
|
|
(2) |
|
|
(0.04) |
|
|
(14) |
|
|
(0.24) |
|
|
(4) |
|
|
(0.07) |
|
|||||||||
Adjustments, net of tax |
14 |
|
|
0.24 |
|
|
9 |
|
|
0.14 |
|
|
46 |
|
|
0.78 |
|
|
15 |
|
|
0.25 |
|
|||||||||
Adjusted net income |
$ |
199 |
|
|
$ |
3.40 |
|
|
$ |
285 |
|
|
$ |
4.79 |
|
|
$ |
459 |
|
|
$ |
7.83 |
|
|
$ |
469 |
|
|
$ |
7.79 |
|
|
__________________ |
||||||||||||||||||||||||||||||||
(1) Beginning in the third quarter of 2020, reflects non-recurring costs associated with acquisitions, including various transaction and integration costs.
|
|
||||
|
||||
RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES (CONTINUED) |
||||
2021 GUIDANCE |
||||
Net income per diluted share (1) |
$ |
11.65 |
|
|
Adjustments: |
|
|||
Acquisition-related expenses |
1.13 |
|
||
Amortization of intangible assets |
0.81 |
|
||
Other |
0.16 |
|
||
Subtotal, adjustments |
2.10 |
|
||
Income tax effect (2) |
(0.50) |
|
||
Adjustments, net of tax |
1.60 |
|
||
Adjusted net income per diluted share |
$ |
13.25 |
|
|
__________________ |
||||
(1) Computations assume approximately 58.6 million diluted weighted average shares outstanding.
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20210728005899/en/
Investor Contact:
Media Contact:
Source: